KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Equity (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Return on Equity data on record, last reported at 0.15% in Q4 2025.

  • For Q4 2025, Return on Equity rose 7.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.15%, up 7.0%, while the annual FY2025 figure was 0.4%, 1.0% up from the prior year.
  • Return on Equity reached 0.15% in Q4 2025 per ACAD's latest filing, up from 0.11% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.23% in Q3 2024 and bottomed at 0.52% in Q4 2022.
  • Average Return on Equity over 5 years is 0.2%, with a median of 0.3% recorded in 2023.
  • Peak YoY movement for Return on Equity: fell -22bps in 2022, then surged 63bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.3% in 2021, then tumbled by -73bps to 0.52% in 2022, then surged by 70bps to 0.15% in 2023, then skyrocketed by 148bps to 0.07% in 2024, then surged by 96bps to 0.15% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.15% in Q4 2025, 0.11% in Q3 2025, and 0.07% in Q2 2025.